ClinicalTrials.gg
CompletedNCT04166773SYNERGY-NASHUpdated Jan 24, 2025Results posted

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of Tirzepatide and Placebo in Nonalcoholic Steatohepatitis, sponsored by Eli Lilly and Company. Completed at 112 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
82nd of 460
190 · median 56
Started
2019
with 61 others
Phase 2
192 of 547
15 open now
Registered
317th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 82nd largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 317th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).

03

Conditions studied

  • Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Participants must have a (BMI) ≥27 kilograms per square meter (kg/m²) and ≤50 kg/m² with stable body weight for at least 3 months
  • Participants with or without type 2 diabetes mellitus (T2DM)

    • If with T2DM, (HbA1c) ≤9.5%
  • Participants must be willing to undergo baseline and endpoint liver
  • Participants must have histologic diagnosis of NASH with stage 2 or 3 fibrosis by liver biopsy
  • Participants must not have known or suspected alcohol abuse (>14 units/week for women and >21 units/week for men) or active substance abuse
  • Participants must not have evidence of cirrhosis or other forms of liver disease
  • Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 6 months
  • Participants must not have active cancer within the last 5 years
  • Participants must not have uncontrolled high blood pressure
  • Participants must not have renal impairment with estimated (eGFR) \<30 milliters/minute/1.73m²; for participants on metformin, eGFR \<45 mL/min/1.73m²
  • Participants must not have a diagnosis of type 1 diabetes
  • Participants must not have a history of pancreatitis (acute or chronic)
  • Participants must not have calcitonin ≥35 nanograms per liter
  • Participant must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)
  • Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of and not using adequate method (adequate contraceptive measures as required by local regulation or practice)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    5 mg Tirzepatide

    5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.

    Drug: Tirzepatide

  • Experimental
    10 mg Tirzepatide

    10 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    15 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Placebo administered SC once a week.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology

    NASH resolution is defined as the absence of fatty liver disease or simple steatosis without steatohepatitis; the absence of hepatocellular ballooning (nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) 0 for ballooning); with or without mild lobular inflammation (NAS 0 or 1 for inflammation); and any value for steatosis. No worsening of fibrosis is defined as no increase in fibrosis stage from baseline to Week 52.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of NASH on Liver Histology

    NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Evaluation of fibrosis stage was based on the nonalcoholic steatohepatitis clinical research network (NASH CRN) fibrosis staging system, which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. Participants were evaluated with the NASH CRN scoring system with ≥1-point reduction without worsening of NASH (defined as no increase in the NAS score).

    Time frame: Week 52

  2. Percentage of Participants With ≥1 Point Increase in Fibrosis Stage on Liver Histology

    Participants were evaluated with the NASH CRN scoring system with ≥1 stage increase in fibrosis.

    Time frame: Week 52

  3. Percentage of Participants That Achieve a ≥2 Point Decrease in NAFLD (Non-alcoholic Fatty Liver Disease) Activity Score (NAS) on Liver Histology, With ≥1 Point Reduction in at Least 2 NAS Components

    Hepatic histological improvement in NAS was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in at least 2 NAS components (lobular inflammation, hepatocellular ballooning or steatosis). The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8, with the higher score indicating more aggressive disease.

    Time frame: Week 52

  4. Mean Absolute Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

    MRI-PDFF is an established method that enables quantification of fat content in the liver. The value of whole liver fat as assessed by MRI-PDFF is expressed in percentage (%) and ranges from 0 to 100% with higher values representing higher liver fat level. Least square (LS) mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Diabetes Flag (DIABFL) + REGION1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline to Week 52

  5. Mean Change From Baseline in Body Weight

    Change in body weight at the end of 52 weeks measured in kilogram (kg) using a calibrated scale. LS mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + DIABFL + REGION1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline to Week 52

07

Results

Posted Jan 24, 2025

Participant flow

Participant flow — Overall Study
Milestone5 Milligram (mg) Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Started47474848
Received at least one dose of study drug47474848
Completed40444338
Not completed73510
Withdrew: Adverse event2021
Withdrew: Lost to follow-up4213
Withdrew: Physician decision0001
Withdrew: Withdrawal by subject1125

Outcome measures

PrimaryPercentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology

NASH resolution is defined as the absence of fatty liver disease or simple steatosis without steatohepatitis; the absence of hepatocellular ballooning (nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) 0 for ballooning); with or without mild lobular inflammation (NAS 0 or 1 for inflammation); and any value for steatosis. No worsening of fibrosis is defined as no increase in fibrosis stage from baseline to Week 52.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology51.8463.1373.9212.62
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.45 · 95% CI 2.27 to 24.44Odds ratio, Confidence Interval (CI), and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 11.86 · 95% CI 3.59 to 39.11Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 19.63 · 95% CI 5.73 to 67.25Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
SecondaryPercentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of NASH on Liver Histology

NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Evaluation of fibrosis stage was based on the nonalcoholic steatohepatitis clinical research network (NASH CRN) fibrosis staging system, which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. Participants were evaluated with the NASH CRN scoring system with ≥1-point reduction without worsening of NASH (defined as no increase in the NAS score).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of NASH on Liver Histology
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of NASH on Liver Histology59.2153.3554.332.51
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.025 · Odds ratio (or): 3.01 · 95% CI 1.15 to 7.90Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.074 · Odds ratio (or): 2.37 · 95% CI 0.92 to 6.13Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.063 · Odds ratio (or): 2.47 · 95% CI 0.95 to 6.40Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
SecondaryPercentage of Participants With ≥1 Point Increase in Fibrosis Stage on Liver Histology

Participants were evaluated with the NASH CRN scoring system with ≥1 stage increase in fibrosis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥1 Point Increase in Fibrosis Stage on Liver Histology
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants With ≥1 Point Increase in Fibrosis Stage on Liver Histology12.049.815.5313.03
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.893 · Odds ratio (or): 0.91 · 95% CI 0.25 to 3.40Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.647 · Odds ratio (or): 0.73 · 95% CI 0.18 to 2.87Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.246 · Odds ratio (or): 0.39 · 95% CI 0.08 to 1.91Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
SecondaryPercentage of Participants That Achieve a ≥2 Point Decrease in NAFLD (Non-alcoholic Fatty Liver Disease) Activity Score (NAS) on Liver Histology, With ≥1 Point Reduction in at Least 2 NAS Components

Hepatic histological improvement in NAS was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in at least 2 NAS components (lobular inflammation, hepatocellular ballooning or steatosis). The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8, with the higher score indicating more aggressive disease.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants That Achieve a ≥2 Point Decrease in NAFLD (Non-alcoholic Fatty Liver Disease) Activity Score (NAS) on Liver Histology, With ≥1 Point Reduction in at Least 2 NAS Components
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants That Achieve a ≥2 Point Decrease in NAFLD (Non-alcoholic Fatty Liver Disease) Activity Score (NAS) on Liver Histology, With ≥1 Point Reduction in at Least 2 NAS Components81.0286.5588.7738.09
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.94 · 95% CI 2.41 to 20.00Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 10.46 · 95% CI 3.36 to 32.61Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 12.85 · 95% CI 3.87 to 42.65Odds ratio, CI, and p-value for endpoint measures are from logistic regression model with baseline diabetes status, region, treatment as factors.
SecondaryMean Absolute Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

MRI-PDFF is an established method that enables quantification of fat content in the liver. The value of whole liver fat as assessed by MRI-PDFF is expressed in percentage (%) and ranges from 0 to 100% with higher values representing higher liver fat level. Least square (LS) mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Diabetes Flag (DIABFL) + REGION1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · absolute percentage of liver fat
Mean Absolute Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
absolute percentage of liver fat5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Absolute Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)-10.12 ± 1.165-10.15 ± 1.071-11.34 ± 1.107-1.31 ± 1.142
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -8.81 · 95% CI -12.04 to -5.58
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -8.83 · 95% CI -11.93 to -5.73
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.02 · 95% CI -13.17 to -6.87
SecondaryMean Change From Baseline in Body Weight

Change in body weight at the end of 52 weeks measured in kilogram (kg) using a calibrated scale. LS mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + DIABFL + REGION1 + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Kilogram (kg)
Mean Change From Baseline in Body Weight
Kilogram (kg)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Body Weight-11.46 ± 1.404-14.22 ± 1.380-17.88 ± 1.376-1.04 ± 1.392
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -10.42 · 95% CI -14.32 to -6.52
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -13.19 · 95% CI -17.05 to -9.32
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -16.84 · 95% CI -20.71 to -12.98

Adverse events

Collected over Baseline Up to Week 56. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide0/47 (0%)5/47 (10.6%)43/47 (91.5%)
10 mg Tirzepatide0/47 (0%)4/47 (8.5%)43/47 (91.5%)
15 mg Tirzepatide0/48 (0%)0/48 (0%)44/48 (91.7%)
Placebo0/48 (0%)3/48 (6.3%)40/48 (83.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Ovarian neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/270/260/291/27
Endometrial thickeningReproductive system and breast disorders0/270/260/291/27
Developmental hip dysplasiaCongenital, familial and genetic disorders1/470/470/480/48
Large intestine polypGastrointestinal disorders0/471/470/480/48
PneumoperitoneumGastrointestinal disorders0/471/470/480/48
Umbilical herniaGastrointestinal disorders0/471/470/480/48
CholecystitisHepatobiliary disorders0/471/470/480/48
Covid-19 pneumoniaInfections and infestations1/470/470/480/48
HypokalaemiaMetabolism and nutrition disorders1/470/470/480/48
Transient ischaemic attackNervous system disorders1/470/470/480/48
Most frequent other events
Showing 10 of 277
Most frequent other events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
NauseaGastrointestinal disorders17/4716/4721/486/48
DiarrhoeaGastrointestinal disorders15/4717/4713/4811/48
ConstipationGastrointestinal disorders11/479/477/483/48
Decreased appetiteMetabolism and nutrition disorders9/4710/4711/481/48
Covid-19Infections and infestations5/476/479/484/48
DyspepsiaGastrointestinal disorders2/478/472/482/48
VomitingGastrointestinal disorders3/473/477/481/48
Abdominal painGastrointestinal disorders6/473/474/483/48
Abdominal pain upperGastrointestinal disorders6/472/470/482/48
DizzinessNervous system disorders2/476/474/482/48

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean55.00 ± 11.6254.30 ± 12.0854.90 ± 10.0253.50 ± 11.6054.40 ± 11.28
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Female27262927109
Male2021192181
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Hispanic or Latino1915171869
Not Hispanic or Latino2125272497
Unknown or Not Reported774624
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
American Indian or Alaska Native11103
Asian566522
Native Hawaiian or Other Pacific Islander00000
Black or African American01001
White41394143164
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Belgium00101
France772622
Israel32005
Italy10236
Japan444416
Mexico133310
Poland10001
Spain10618
United Kingdom154414
United States28262627107
08

Study locations

112 sites
  • University of Alabama-The Kirklin Clinic
    Birmingham, Alabama 35205, United States
  • Synexus Clinical Research US, Inc.
    Chandler, Arizona 85224, United States
  • Fresno Clinical Research Center
    Fresno, California 93720, United States
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • UCSD - Altman Clinical and Translational Research Institute (ACTRI)
    La Jolla, California 92037, United States
  • National Research Institute - Wilshire
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Diabetes Medical Center of California
    Northridge, California 91325, United States
  • Velocity Clinical Research, Panorama City
    Panorama City, California 91402, United States
  • Inland Empire Clinical Trials, LLC
    Rialto, California 92377, United States
  • Velocity Clinical Research, Santa Ana
    Santa Ana, California 92704, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Alliance for Multispecialty Research, LLC
    Coral Gables, Florida 33134, United States
  • Research Centers of America ( Hollywood )
    Hollywood, Florida 33024, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32204, United States
  • IHS Health Research
    Kissimmee, Florida 34741, United States
  • Accel Research Sites - Maitland Clinical Research Unit
    Maitland, Florida 32751, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • The Center for Digestive Health
    Orlando, Florida 32803, United States
  • Synexus Clinical Research US, Inc.
    Orlando, Florida 32806, United States
  • Synexus Clinical Research US, Inc.
    The Villages, Florida 32162, United States
  • Synexus Clinical Research
    Chicago, Illinois 60602, United States
  • Indiana University Health Hospital
    Indianapolis, Indiana 46202, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • The National Diabetes & Obesity Research Institute
    Biloxi, Mississippi 39532, United States
  • Southern Therapy and Advanced Research (STAR) LLC
    Jackson, Mississippi 39216, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Buffalo Clinical and Translational Research Center
    Buffalo, New York 14203, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Diabetes & Endocrinology Consultants, PC
    Morehead City, North Carolina 28557, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • WR-Clinsearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Radiant Research - Dallas North
    Dallas, Texas 75231, United States
  • Liver Center of Texas, PLLC
    Dallas, Texas 75234-7858, United States
  • Texoma Medical Center
    Denison, Texas 75020, United States
  • Texas Diabetes & Endocrinology, P.A.
    Round Rock, Texas 78681, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Synexus Clinical Research US, Inc.
    San Antonio, Texas 78229, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • National Clinical Research, Inc
    Richmond, Virginia 23294, United States
  • Virginia Commonwealth University (VCU) Medical Center
    Richmond, Virginia 23298, United States
  • Harborview Medical Center/University of Washington
    Seattle, Washington 98104, United States
  • Antwerp University Hospital
    Edegem, Antwerpen 2650, Belgium
  • UZ Brussel
    Brussels, Bruxelles-Capitale, Région De 1090, Belgium
  • UZ Gent
    Gent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven
    Leuven, Vlaams-Brabant 3000, Belgium
  • AZ Delta vzw
    Roeselare, West-Vlaanderen 8800, Belgium
  • CHU Bordeaux Haut-Leveque
    Pessac, Aquitaine 33600, France
  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren
    Limoges, Haute-Vienne 87042, France
  • Centre Hospitalier Universitaire d'Angers
    Angers, Maine-et-Loire 49933, France
  • Groupe Hospitalier Mutualiste Les Portes du Sud
    Vénissieux, Rhône-Alpes 69200, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Rhône 69494 Cédex, France
  • Pitie Salpetriere University Hospital
    Paris, 75013, France
  • Hôpital Saint Antoine
    Paris, 75571, France
  • Sheba Medical Center
    Ramat Gan, HaMerkaz 5265601, Israel
  • Rambam Health Care Campus
    Haifa, HaTsafon 3109601, Israel
  • Galilee Medical Center
    Nahariya, HaTsafon 2210001, Israel
  • Hadassah Medical Center
    Jerusalem, Yerushalayim 9112001, Israel
  • Shaare Zedek Medical Center
    Jerusalem, Yerushalayim 9778419, Israel
  • Carmel Hospital
    Haifa, 3436212, Israel
  • A.O.U. Policlinico Paolo Giaccone
    Palermo, Sicilia 90127, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti Di Foggia
    Foggia, 71100, Italy
  • Ospedale Santa Maria Goretti
    Latina, 04100, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Aichi Medical University Hospital
    Nagakute-shi, Aichi-ken 480-1195, Japan
  • JCHO Hokkaido Hospital
    Sapporo-shi, Hokkaido 062-8618, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • National Hospital Organization Yokohama Medical Center
    Yokohama, Kanagawa 2458575, Japan
  • JADECOM Nara City Hospital
    Nara-Shi, Nara-Ken 630-8305, Japan
  • Hirakata kohsai Hospital
    Higashi-cho, Hirakata-city, Osaka 573-0153, Japan
  • Osaka Saiseikai Suita hospital
    Suita, Osaka 564-0013, Japan
  • Shimane University Hospital
    Izumo, Shimane 693-0021, Japan
  • Tokyo Medical And Dental University Medical Hospital
    Bunkyō, Tokyo 113-8519, Japan
  • Fukuiken Saiseikai Hospital
    Fukui, 918-8503, Japan
  • Gifu Municipal Hospital
    Gifu, 500-8323, Japan
  • Kumamoto Shinto General Hospital
    Kumamoto, 862-8655, Japan
  • University Hospital,Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, 951-8520, Japan
  • Saga University Hospital
    Saga, 849-8501, Japan
  • Yamagata University Hospital
    Yamagata, 990-9585, Japan
  • Phylasis Clinicas Research
    Cuautitlan Izcalli, Distrito Federal 54769, Mexico
  • Grupo Medico Camino Sc
    Mexico City, Distrito Federal 3310, Mexico
  • Christus Muguerza Hospital Sur
    Monterrey, Nuevo León 64988, Mexico
  • Centro de Investigación y Gastroenterología
    Cuauhtémoc, 6700, Mexico
  • Synexus Polska Sp. z o.o. Oddzial w Warszawie
    Warsaw, Mazowieckie 02-672, Poland
  • Synexus Polska Oddział w Lodzi
    Lodz, Łódzkie 90-127, Poland
  • Clínica Juaneda
    Palma de Mallorca, Balears [Baleares] 7014, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid, Comunidad De 28034, Spain
  • Instituto de Ciencias Médicas
    Alicante, 3004, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, 28222, Spain
  • Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
    Sevilla, 41003, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • Queen Elizabeth Hospital Birmingham
    Birmingham, England B15 2TH, United Kingdom

Showing the first 100 of 112 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Dec 2023, 48 months.

Results were first posted in Jan 2025, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 48 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2019
First posted
Nov 18, 2019
StartActual
Nov 19, 2019
Primary completionActual
Dec 11, 2023
CompletionActual
Jan 10, 2024
Results first posted
Jan 24, 2025
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04166773
Responsible party
Sponsor
First posted
Nov 18, 2019
Start date
Nov 19, 2019
Primary completion
Dec 11, 2023
Completion
Jan 10, 2024
Results posted
Jan 24, 2025
Last update
Jan 24, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion